Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIR-2218 in chronic HBV infection
NCT04507269Phase 2Completed
- Sponsor
- Brii Biosciences
- Start
- Aug 2020
- Primary completion
- Sep 2021
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing VIR-2218 with Placebo (2 arms). Primary endpoints: Incidence of Treatment-emergent Adverse Events up to 48 weeks and Clinical Assessments Including But Not Limited to Laboratory Test Results up to 48 weeks. Started Aug 2020; status: completed.
02
Drugs
elebsiran
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04507269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04507269.